* MAP to suspend development of pediatric asthma drug

* Says to focus on migraine drug

* MAP shares down as much as 16 pct (Adds comments from company, analyst; updates stock movement)

By Esha Dey

BANGALORE, July 9 (Reuters) - MAP Pharmaceuticals Inc (MAPP.O: Quote, Profile, Research) said it plans to suspend development of its experimental pediatric asthma drug, after its licensing partner AstraZeneca (AZN.L: Quote, Profile, Research) terminated a collaboration on the drug.

The drug, Unit Dose Budesonide, had earlier this year failed to meet the main goals of a late-stage trial in children aged one year to eight years with mild asthma.

"The drug is essentially dead," Wedbush Morgan Securities analyst Liana Moussatos said, adding that the news was not that big a hit to the company given the recent promising results from its migraine drug trial.

MAP said it received the termination notice from AstraZeneca reverting all rights to MAP, on Wednesday.

"It is not an issue that the drug does not work, but rather an issue with the study that did not achieve statistically significant outcomes," MAP's Chief Financial Officer Christopher Chai said.